Aberrant activation of CYR61 enhancers in colorectal cancer development

Abstract

Background High expression of secreted matricellular protein cysteine-rich 61 ( CYR61 ) correlates with poor prognosis in colorectal cancer (CRC). Aberrant enhancer activation has been shown to correlate with expression of key genes involved in cancer progression. However, such mechanisms in CYR61 transcription regulation remain unexplored. Methods Expression of CYR61 was determined by immunohistochemistry (IHC), quantitative real-time PCR (qRT-PCR) and western blotting (WB) in CRC patients paraffin specimens and colon cell lines. ChIP-seq data of enhancer-characteristic histone modifications, in CRC tissues from the Gene Expression Omnibus (GEO) database, were reanalyzed to search for putative enhancers of CYR61 . Dual-luciferase reporter assay was used to detected enhancer activity. Physical interactions between putative enhancers and CYR61 promoter were detected by chromosome conformation capture (3C) assay. Histone modification and transcription factors (TFs) enrichment were detected by ChIP-qPCR. Additionally, biological function of enhancers was investigated by transwell migration assays. Results CRC tissues and cell lines expressed higher level of CYR61 than normal colon mucosa. Three putative enhancers located downstream of CYR61 were found in CRC tissues by ChIP-seq data reanalysis. Consistent with the ChIP-seq analysis results in the GEO database, the normal colon mucosal epithelial cell line NCM460 possessed no active CYR61 enhancers, whereas colon cancer cells exhibited different patterns of active CYR61 enhancers. HCT116 cells had an active Enhancer3, whereas RKO cells had both Enhancer1 and Enhancer3 active. Pioneer factor FOXA1 promoted CYR61 expression by recruiting CBP histone acetyltransferase binding and increasing promoter-enhancer looping frequencies and enhancer activity. CBP knockdown attenuated H3K27ac enrichment, promoter-enhancer looping frequencies, and enhancer activity. Small molecule compound 12-O-tetradecanoyl phorbol-13-acetate (TPA) treatment, which stimulated CYR61 expression, and verteporfin (VP) treatment, which inhibited CYR61 expression, confirmed that the enhancers regulated CYR61 expression. Knockdown and ectopic expression of CYR61 rescued cell migration changes induced by over-expressing and knockdown of FOXA1, respectively. Conclusions CYR61 enhancer activation, mediated by FOXA1 and CBP, occurs during CRC progression to up-regulate CYR61 expression and promote cell migration in CRC, suggesting inhibition of recruitment of FOXA1 and/or CBP to CYR61 enhancers may have therapeutic imp...

Single-Cell RNA Sequencing With Combined Use of Bulk RNA Sequencing to Reveal Cell Heterogeneity and Molecular Changes at Acute Stage of Ischemic Stroke in Mouse Cortex Penumbra Area

“…In our results, both Cyr61 in astrocytes and Sgk3 in oligodendrocytes are overexpressed and these genes could be potential therapeutic targets in this phase. Despite the lack of research on ischemic stroke, previous studies have suggested that the Cyr61 gene is closely associated with the proliferation of stressed and tumoral cells ( Schwarz et al, 2002 ; Xie et al, 2019 ; Sun et al, 2020 ). Overexpression of the Cyr61 gene may help astrocytes survive under acute ischemic stroke conditions.…”

Cyclooxygenase 2-Regulated Genes an Alternative Avenue to the Development of New Therapeutic Drugs for Colorectal Cancer

“…Cyr61/CNN1 has been described as potential serum marker for CRC (Song et al, 2017), whereas Cyr61 expression in the tumor tissue indicates poor prognosis in colon cancer patients being statistically associated with greater mortality (Jeong et al, 2014). Altered activation of CYR61 gene enhancers occurs during CRC development, being CYR61 expression induced by FOXA1 and CBP in colon cancer cells pointing at both transcription factors as targets for CRC treatment (Xie et al, 2019). Interestingly, PGF2a through FP receptors can upregulate the expression of CYR61 mRNA (Xu et al, 2009).…”

Androgen Receptor-Activated Enhancers Simultaneously Regulate Oncogene TMPRSS2 and lncRNA PRCAT38 in Prostate Cancer

“…We recently characterized CYR61 enhancers that play important roles in promoting cell migration during colon cancer progression [25]. In this study, to better understand enhancer regulation in cancer, we show the epigenetic co-regulation of TMPRSS2 and PRCAT38 via eRNA transcription, enhancer-promoter interaction, and gene regulation by transcription factors, revealing a co-regulatory function of two enhancers, denoted by E1 and E2 in the transcription of PRCAT38 and TMPRSS2 .…”